Lexaria Announces Attendance at Two Cannabis Investment Conferences, and Issues Shares for Debt Kelowna, BC /

Lexaria Announces Attendance at Two Cannabis

Investment Conferences, and Issues Shares for Debt

Kelowna, BC / August 29, 2017 / Lexaria Bioscience Corp

(OTCQB:LXRP) (CSE:LXX) (the Company or Lexaria ) announces it is attending

and exhibiting at the Investorshub International Cannabis Conference in Los

Angeles on September 1-2, held at the JW Marriott downtown. Chris Bunka, CEO of

Lexaria, will be giving a presentation on the latest technology available to

benefit the cannabis industry.

On September 7-8, Lexaria is attending and exhibiting at The

Institutional Capital & Cannabis Conference (East) in Miami Beach. This

conference is targeted at high net worth investors, family offices and

institutions as an East Coast follow up to an earlier sold-out event in

Meanwhile, Lexaria has received and executed a notice of

conversion related to certain convertible debt, extinguishing a $45,000

convertible debt plus interest for 307,500 restricted common shares at the

contracted conversion price of US$0.15. Lexaria has also issued 32,433 common

shares to settle US$12,000 of debt to a director, at a conversion price of

The securities referred to herein will not be or have not

been registered under the United States Securities Act of 1933, as amended, and

may not be offered or sold in the United States absent registration or an

applicable exemption from registration requirements.

Lexaria Bioscience Corp. has developed and out-licenses its

disruptive technology that promotes healthier ingestion methods, lower overall

dosing and higher effectiveness of lipophilic active molecules. Lexaria has

multiple patents pending in over 40 countries around the world and was granted

its first patents in the USA and in Australia related to edible forms of

cannabinoids. Lexaria s technology provides increases in intestinal absorption

rates; more rapid delivery to the bloodstream; and important taste-masking

benefits, for orally administered bioactive molecules including cannabinoids,

vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other

FOR FURTHER INFORMATION PLEASE CONTACT:

FORWARD-LOOKING STATEMENTS

This release includes

forward-looking statements. Statements which are not historical facts are

forward-looking statements. The Company makes forward-looking public statements

concerning its expected future financial position, results of operations, cash

flows, financing plans, business strategy, products and services, competitive

positions, growth opportunities, plans and objectives of management for future

operations, including statements that include words such as "anticipate," "if,"

"believe," "plan," "estimate," "expect," "intend," "may," "could," "should,"

"will," and other similar expressions are forward-looking statements, including

but not limited to: that any additional stock warrants or stock options will be

exercised. Such forward-looking statements are estimates reflecting the

Company's best judgment based upon current information and involve a number of

risks and uncertainties, and there can be no assurance that other factors will

not affect the accuracy of such forward-looking statements. Factors which could

cause actual results to differ materially from those estimated by the Company

include, but are not limited to, government regulation, managing and maintaining

growth, the effect of adverse publicity, litigation, competition, the patent

application and approval process and other factors which may be identified from

time to time in the Company's public announcements and filings. There is no

assurance that existing capital is sufficient for the Company's needs or that it

will be able to raise additional capital. There is no assurance that Lexaria

will successfully complete any other contemplated or existing technology license

agreements. There is no assurance that any planned corporate activity, business

venture, or initiative will be pursued, or if pursued, will be successful. There

is no assurance that any of Lexaria s postulated uses, benefits, or advantages

for the patented and patent-pending technology will in fact be realized in any

manner or in any part. No statement herein has been evaluated by the Food and

Drug Administration (FDA). Lexaria Energy Foods and ViPovaTM products

are not intended to diagnose, treat, cure or prevent any disease.

The CSE has not reviewed and does not accept responsibility

for the adequacy or accuracy of this release.